While I have a few reservations, especially with net debt, and slow down in cash flow, I believe this stock is a buy for the long-term investor. They have a unique product with hospitals somewhat dependent on their supply. The Asian opportunities are also promising, and Immulab will be a key driver once their expansion plans are realized in 2024.
The dividend, whilst modest, reflects a positive outlook, and the desire of management to meet shareholder expectations. As I bought in (via Quantum) at a modest price the return is quite adequate, and with good future prospects, I am happy to hold.
While I have a few reservations, especially with net debt, and...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
-0.005(1.28%) |
Mkt cap ! $620.7M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.5¢ | 37.5¢ | $22.88K | 59.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 3149 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 40000 | 1 |
View Market Depth
| Last trade - 11.19am 16/06/2025 (20 minute delay) ? |
| PGC (ASX) Chart |